For Potential Investors:
In order to take the lead product through Phase II Clinical Trials in 2011, the Company anticipates a total funding of approximately $20 million. We believe that the Company will have a range of exit opportunities after it attains seminal milestones, such as completion of Phase II Clinical Trials, post the $20 million investment. With a pipeline of innovative products, we believe that AllTranz will have a range of exit opportunities, including potential licensing, partnering or an IPO, as well as the revenue stream generated through the launch of the lead product in 2015. The total financing sought at this time is $8 to $10 million dollars in order to complete the lead product Phase I Clinical Trial and move two other products through preclinical toxicology testing.
Current Financial Support:
Kentucky Seed Capital Fund - $250,000
Commonwealth Seed Capital - $250,000
Bluegrass Angels - $360,000
KSTC GAP fund - $400,000
Kentucky Economic Development Finance Authority Forgivable Loan - $500,000